Loading...
Loading...
CALA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.4M |
| Operating I/L | -11.4M |
| Other Income/Expense | 2.3M |
| Interest Income | 0.1M |
| Pretax | -9.1M |
| Income Tax Expense | -19.3M |
| Net Income/Loss | 10.2M |
Calithera Biosciences, Inc. is a clinical-stage bio-pharmaceutical company specializing in the development of small molecule compounds for cancer treatment. Its product portfolio includes INCB001158, an arginase inhibitor in Phase 1/2 clinical trial for hematology and oncology; CB-280, an oral arginase inhibitor for cystic fibrosis and chronic airway infection; ATG-037, a CD73 inhibitor; and CB-668, an IL4I1 inhibitor. The company generates revenue through licensing agreements with Mars, Inc., Pfizer, Incyte Corporation, and Antengene Corporation Ltd., for the development and commercialization of its products in the healthcare market.
